<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434445</url>
  </required_header>
  <id_info>
    <org_study_id>UW12342</org_study_id>
    <nct_id>NCT02434445</nct_id>
  </id_info>
  <brief_title>Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients</brief_title>
  <official_title>Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hong Kong Society of Nephrology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the use of novel plasma and urinary biomarkers to predicte the
      development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers
      investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA,
      plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced
      cirrhotic patients who have or have not developed hepatorenal syndrome and compared between
      the two groups. These biomarkers will also be correlated with the occurence of hepatorenal
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigated the use of novel plasma and urinary biomarkers to predicte the
      development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers
      tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma
      BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic
      patients who have or have not developed hepatorenal syndrome and compared between the two
      groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatorenal syndrome</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic renal impairment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Hepatorenal syndrome group</arm_group_label>
    <description>Patients with advanced cirrhosis who develope hepatorenal syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hepatorenal syndrome group</arm_group_label>
    <description>Patients with advanced cirrhosis who do not hepatorenal syndrome</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      patient's serum and urine samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Patients with co-existing renal diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Desmond Yap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Desmond Yap, MD</last_name>
    <phone>85222553879</phone>
    <email>desmondy@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital, Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desmond Yap, MD</last_name>
      <phone>85222553879</phone>
      <email>desmondy@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Desmond Yat-Hin Yap</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

